Association between Type I interferon and depletion and dysfunction of endothelial progenitor cells in C57BL/6 mice deficient in both apolipoprotein E and Fas ligand. 2018

Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, China.

Patients with systemic lupus erythematosus (SLE) have a tremendously increased risk for cardiovascular disease (CVD), which could not be accounted in entirety by traditional Framingham risk factors. To study whether the accelerated atherosclerosis in SLE patients is mediated by type I interferon (IFN-I) through the regulation of endothelial progenitor cells (EPCs), we created a line of C57BL/6 mice with deficiency in both apolipoprotein E (ApoE-/-) and fas ligand (FasL-/-, gld.). As expected, the resultant gld. ApoE-/- mice exhibited both aggravated lupus-like disease and atherosclerosis under normal diet. Increased expression of IFN-I-stimulated genes (ISGs) was closely associated with depletion and dysfunction of EPCs, as well as with accelerated atherosclerotic lesion in gld. ApoE-/- mice. While only IFN-α instead of other interventions, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IRS423 and IRS661, impaired EPC function in vitro. Mechanistically, activation or inhibition of the TLR7/9 signaling could modulate EPC number and function in vivo. Decreased proliferation rate and increased apoptotic rate of EPCs induced by IFN-α might contribute to the results to a certain extent. Thus, our data suggest that excessive expression of IFN-I through the activation of TLR7/9 signaling may induce accelerated atherosclerosis in lupus through the depletion or dysfunction of EPCs, suggesting that targeting IFN-I might have potential therapeutic effects on both lupus disease and premature atherosclerosis in SLE patients.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000074085 Mice, Knockout, ApoE Strains of mice that contain genetic disruptions (knockout) of APOLIPOPROTEINS E genes. They are used as models for ATHEROSCLEROSIS research. Apo E Knockout Mice,ApoE Knockout Mice,Knockout Mice, ApoE,Mice, ApoE Knockout
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
January 2005, Physiological research,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
August 2004, Arteriosclerosis, thrombosis, and vascular biology,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
June 2001, Arteriosclerosis, thrombosis, and vascular biology,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
June 2016, Translational research : the journal of laboratory and clinical medicine,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
May 2010, Lipids in health and disease,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
May 2019, The Journal of nutritional biochemistry,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
August 2006, The British journal of nutrition,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
May 2020, European journal of pharmacology,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
November 2007, Arthritis and rheumatism,
Linyu Geng, and Shiying Wang, and Xia Li, and Dandan Wang, and Haifeng Chen, and Jinyun Chen, and Yue Sun, and Weiwei Chen, and Genhong Yao, and Xiang Gao, and Wanjun Chen, and Songtao Shi, and Xuebing Feng, and Lingyun Sun
January 2008, Stroke,
Copied contents to your clipboard!